Oral bisphosphonates and risk of esophageal cancer: A dose-intensity analysis in a nationwide population

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 6, 2012, Pages 993-995

  Ho, Yunn Fang ^a   Lin, Jaw Town ^b,d   Wu, Chun Ying ^c,e,f  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (China)

^f TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; RISEDRONIC ACID;

ARTICLE; ASIAN; CANCER RISK; CONTROLLED STUDY; DOSE RESPONSE; DRUG EXPOSURE; ESOPHAGUS CANCER; HUMAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; TAIWAN; TREATMENT DURATION;

CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; HUMANS; RESEARCH DESIGN; RISK FACTORS; TAIWAN;

EID: 84862882948     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0259     Document Type: Article

References (8)

1. US Food and Drug Administration. Background Document for Meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee. Silver Spring, MD: US Food and Drug Administration; 2011 Sep 9 [cited 2012 Feb]. Available from: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/Drug SafetyandRiskManagementAdvisoryCommittee/UCM270958.pdf.
2. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360:89-90.
3. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. Br Med J 2010;341:c4444.
4. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010;304:657-63.
5. Nguyen DM, Schwartz J, Richardson P, El-Serag HB. Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Dig Dis Sci 2010;55:3404-7.
6. Wu CY, WuMS, Kuo KN, Wang CB, Chen YJ, Lin JT. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol 2010;28:2952-7.
7. Holen I, Coleman RE. Bisphosphonates as treatment of bone metastases. Curr Pharm Des 2010;16:1262-71.
8. Rennert G, Pinchev M, Rennert HS, Gruber SB. Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol 2011;29:1146-50.